Elwyn Loh

4.7k total citations · 2 hit papers
66 papers, 4.0k citations indexed

About

Elwyn Loh is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Elwyn Loh has authored 66 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 21 papers in Molecular Biology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Elwyn Loh's work include Liver physiology and pathology (10 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Gastric Cancer Management and Outcomes (9 papers). Elwyn Loh is often cited by papers focused on Liver physiology and pathology (10 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Gastric Cancer Management and Outcomes (9 papers). Elwyn Loh collaborates with scholars based in United States, United Kingdom and France. Elwyn Loh's co-authors include Ronald W. Davis, John Cameron, Lewis L. Lanier, Mark M. Davis, Robert T. Elder, John F. Elliott, Kelly S. Oliner, Min Zhu, John L. Rombeau and Richard P. MacDermott and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Elwyn Loh

64 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Polymerase Chain Reaction with Single-Sided Specificity: Analysis of T Cell Receptor δ Chain

1989 565 citations Elwyn Loh, John F. Elliott et al. Science profile →
Evidence for transposition of dispersed repetitive DNA families in yeast

1979 507 citations Elwyn Loh et al. profile →

Peers

Countries citing papers authored by Elwyn Loh

Since Specialization

Citations

This map shows the geographic impact of Elwyn Loh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elwyn Loh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elwyn Loh more than expected).

Fields of papers citing papers by Elwyn Loh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elwyn Loh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elwyn Loh. The network helps show where Elwyn Loh may publish in the future.

Co-authorship network of co-authors of Elwyn Loh

This figure shows the co-authorship network connecting the top 25 collaborators of Elwyn Loh. A scholar is included among the top collaborators of Elwyn Loh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elwyn Loh. Elwyn Loh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer 2015 ·Clinical Cancer Research ·Sameer Doshi, Per Olsson, Yilong Zhang, Min Zhu, Kelly S. Oliner, Elwyn Loh, Juan José Pérez Ruixo	22
2	Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer 2014 ·Clinical Cancer Research ·Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, Ірина Давиденко, Joe Stephenson, Élena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero	92
3	Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor 2013 ·Clinical Cancer Research ·Ian McCaffery, Yanyan Tudor, Hongjie Deng, Rui Tang, Samuel Suzuki, Sunita Badola, Hedy L. Kindler, Charles S. Fuchs, Elwyn Loh, Scott D. Patterson, Li Chen, Jennifer Gansert	54
4	A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC) 2013 ·Journal of Thoracic Oncology ·Bonnie S. Glisson, Andrzej Każarnowicz, Kristiaan Nackaerts, Sergey Orlov, Rodryg Ramlau, Benjamin Besse, Manuel Cobo, Hari Menon, Luis Paz-Ares Rodríguez, Yilong Zhang, Min Zhu, Yizhou Jiang, Elwyn Loh, Jennifer Gansert, Sarita Dubey	4
5	Population Pharmacokinetics of Rilotumumab, a Fully Human Monoclonal Antibody Against Hepatocyte Growth Factor, in Cancer Patients 2013 ·Journal of Pharmaceutical Sciences ·Min Zhu, Sameer Doshi, Per Olsson, Kelly S. Oliner, Juan José Pérez Ruixo, Elwyn Loh, Yilong Zhang	17
6	Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone 2012 ·Clinical Cancer Research ·Charles J. Ryan, Mark Rosenthal, Siobhan Ng, Joshi J. Alumkal, Joel Picus, Gwénaëlle Gravis, Karim Fizazi, Frédéric Forget, Jean-Pascal Machiels, Sandy Srinivas, Min Zhu, Rui Tang, Kelly S. Oliner, Yizhou Jiang, Elwyn Loh, Sarita Dubey, Winald R. Gerritsen	64
7	PRIMARY ANALYSIS AND BIOMARKER EVALUATION: RANDOMIZED PHASE IB/II STUDY OF RILOTUMUMAB (AMG 102) OR GANITUMAB (AMG 479) WITH PANITUMUMAB VERSUS PANITUMUMAB ALONE IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) 2011 ·Annals of Oncology ·Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith Mitchell, Ірина Давиденко, Élena Elez, Kelly S. Oliner, Lisa Chen, Jing Huang, Ian McCaffery, Elwyn Loh, Dominic Smethurst, Eric Van Cutsem	0
8	Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer 2007 ·International Journal of Radiation OncologyBiologyPhysics ·Ezra E.W. Cohen, Dominique Rosine, Daniel J. Haraf, Elwyn Loh, Liji Shen, Antoine Lusinchi, Everett E. Vokes, Jean Bourhis	38
9	Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer 2006 ·International Journal of Gynecological Cancer ·Fernando Cotait Maluf, Aliza Leiser, Carol Aghajanian, Paul Sabbatini, S. Pezzulli, (unknown), Judith K. Wolf, Charles Levenback, Elwyn Loh, David R. Spriggs	27
10	GABAA receptor β isoform protein expression in human alcoholic brain: interaction with genotype 2006 ·Neurochemistry International ·S. Buckley, P. F. Foley, David J. Innes, Elwyn Loh, Yi Shen, S. M. Williams, (unknown), A. E. G. Tannenberg, Peter R. Dodd	15
11	Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination 1999 ·Medical Oncology ·Edward A. Stadtmauer, Donald E. Tsai, Cheryl Sickles, Rosemarie Mick, Selina M. Luger, David Porter, Patricia Mangan, Lynn M. Schuchter, Stephen J. Schuster, Elwyn Loh, (unknown), (unknown), (unknown), Jonni S. Moore, Gordon P. Buzby, (unknown), Malek Kamoun, Leslie E. Silberstein	11
12	Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: Impact on the delivery of local-regional radiation therapy 1999 ·Annals of Oncology ·Halle C. F. Moore, Rosemarie Mick, Lawrence J. Solin, Cheryl Sickles, Patricia Mangan, Selina M. Luger, Kevin R. Fox, Lynn M. Schuchter, Elwyn Loh, David Porter, Stephen J. Schuster, Gordon P. Buzby, Eli Glatstein, Leslie E. Silberstein, Edward A. Stadtmauer	5
13	Regulation of αIIbβ3 Function in Human B Lymphocytes 1998 ·Journal of Biological Chemistry ·(unknown), Elwyn Loh, Gaston Vilaire, Joel Bennett	18
14	Monocyte-chemoattractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosa 1995 ·Gastroenterology ·Hans-Christian Reinecker, Elwyn Loh, D J Ringler, (unknown), John L. Rombeau, Richard P. MacDermott	233
15	Agonist-stimulated Ligand Binding by the Platelet Integrin αIIbβ3 in a Lymphocyte Expression System 1995 ·Journal of Biological Chemistry ·Elwyn Loh, Katherine Beaverson, Gaston Vilaire, Weiwei Qi, Mortimer Poncz, Joel Bennett	26
16	Competitor mRNA fragments for quantitation of cytokine specific transcripts in cell lysates 1993 ·Molecular Immunology ·Danuta Kozbor, Elizabeth Hyjek, (unknown), (unknown), (unknown), Elwyn Loh	32
17	Molecular Analysis of Intrathymic Nicotinic Acetylcholine Receptor 1993 ·Annals of the New York Academy of Sciences ·Lisa M. Wheatley, (unknown), Yi Zheng, Elwyn Loh, Arnold I. Levinson	15
18	Polymerase Chain Reaction with Single-Sided Specificity: Analysis of T Cell Receptor δ Chain breakdown → 1989 ·Science ·Elwyn Loh, John F. Elliott, (unknown), Lewis L. Lanier, Mark M. Davis	565
19	The XLR sequence family: dispersion on the X and Y chromosomes of a large set of closely related sequences, most of which are pseudogenes 1989 ·Nucleic Acids Research ·Henri‐Jean Garchon, Elwyn Loh, William Ho, Laurence Amar, Philip Avner, Mark M. Davis	29
20	Identification and sequence of a fourth human T cell antigen receptor chain 1987 ·Nature ·Elwyn Loh, Lewis L. Lanier, (unknown), Dan R. Littman, Mark M. Davis, Yueh-hsiu Chien, Arthur J. Weiss	139

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact